RBOT · Vicarious Surgical Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Management does not believe that the Company’s cash, cash equivalents and short-term investments balance at March 31, 2026 of $3,682 will be sufficient to support the Company’s operations for the next twelve months from the date of issuance of these financial statements, and accordingly, this raises substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Apr 30, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $29.23M | $33.6M | $40.16M | $47.58M | $43.9M | $22.06M | $9.8M | |
| $1.47M | $2.17M | $4.53M | $6.23M | $6.46M | $2.96M | $861K | |
| $12.03M | $15.2M | $21.88M | $26.86M | $29.72M | $13.2M | $2.33M | |
| $41.78M | $50.03M | $66.56M | $80.67M | $80.08M | $38.22M | $12.99M | |
| -$41.78M | -$50.03M | -$66.56M | -$80.67M | -$80.08M | -$38.22M | -$12.99M | |
| — | — | — | $25K | $200K | $89K | $3000 | |
| — | — | — | — | $1.44M | $20K | $113K | |
| — | -$155K | $3.33M | — | — | — | — | |
| -$42.12M | -$50.18M | -$63.22M | -$71.07M | $5.16M | -$35.21M | -$12.88M | |
| -$42.12M | -$50.18M | -$63.22M | -$71.07M | $5.16M | -$35.21M | -$12.88M | |
| — | — | — | — | $5.16M | -$35.21M | -$12.88M | |
| -$42.14M | -$50.23M | -$63.18M | -$71.06M | $5.16M | — | — | |
| USD/shares | -$10.37 | — | — | -$14.70 | $1.20 | -$10.80 | -$4.80 |
| USD/shares | -$10.37 | — | — | -$14.70 | $1.20 | -$10.80 | -$4.80 |
| shares | — | 6.13M | 5.89M | 4.87M | 4.06M | 3.22M | — |
| shares | — | 6.13M | 5.89M | 4.87M | 4.25M | 3.22M | 2.62M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of other notes payable | 2026-03-31 | USD 371,000 | 10-Q filed 2026-04-30 |
| Line of credit borrowings, including current maturities | 2026-03-31 | USD 257,000 | 10-Q filed 2026-04-30 |
| Operating lease liabilities | 2026-03-31 | USD 6,824,000 | 10-Q filed 2026-04-30 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 21 similar-size Medical Devices companies (of 155 listed).